Characteristics of the 28 CLL patients enrolled on study
| Patient characteristics . | Total . |
|---|---|
| Age, median (range), y | 67 (40-83) |
| ≥65 y, n (%) | 16 (57.1) |
| Female, n (%) | 5 (17.9) |
| Binet stage at diagnosis, n = 28, n (%) | |
| Clinical stage B | 15 (53.6) |
| Clinical stage C | 13 (46.4) |
| ECOG performance status, n = 28, n (%) | |
| 0 | 10 (35.7) |
| 1 | 14 (50) |
| 2 | 4 (14.3) |
| With lymphadenopathy >5 cm, n (%) | 15 (53.5) |
| Interphase cytogenetic abnormalities, n = 25, n (%) | |
| with del (13)(q14.3) | 12 (48) |
| with del (11)(q22.3) | 7 (28) |
| with del (17)(p13.1) | 9 (36) |
| with trisomy 12 | 5 (20) |
| Unmutated IGHV gene segments, n (%) | 21 (84) |
| TP53 mutation (Sanger DNA sequencing), n (%) | 13 (52) |
| No cytogenetics available | 3 (10.7) |
| Prior no. of therapies, median (range) | 3.5 (2-7) |
| Relapsed, n (%) | 16 (57.1) |
| Refractory, n (%) | 11 (39.3) |
| Not known, n (%) | 1 (3.6) |
| Patient characteristics . | Total . |
|---|---|
| Age, median (range), y | 67 (40-83) |
| ≥65 y, n (%) | 16 (57.1) |
| Female, n (%) | 5 (17.9) |
| Binet stage at diagnosis, n = 28, n (%) | |
| Clinical stage B | 15 (53.6) |
| Clinical stage C | 13 (46.4) |
| ECOG performance status, n = 28, n (%) | |
| 0 | 10 (35.7) |
| 1 | 14 (50) |
| 2 | 4 (14.3) |
| With lymphadenopathy >5 cm, n (%) | 15 (53.5) |
| Interphase cytogenetic abnormalities, n = 25, n (%) | |
| with del (13)(q14.3) | 12 (48) |
| with del (11)(q22.3) | 7 (28) |
| with del (17)(p13.1) | 9 (36) |
| with trisomy 12 | 5 (20) |
| Unmutated IGHV gene segments, n (%) | 21 (84) |
| TP53 mutation (Sanger DNA sequencing), n (%) | 13 (52) |
| No cytogenetics available | 3 (10.7) |
| Prior no. of therapies, median (range) | 3.5 (2-7) |
| Relapsed, n (%) | 16 (57.1) |
| Refractory, n (%) | 11 (39.3) |
| Not known, n (%) | 1 (3.6) |
Please see supplemental Table 1 for additional clinical and laboratory details on this cohort.